Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
Loading...
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
BMC
Abstract
The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light
to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG
containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations
when compared with other class of regimens.We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistanceassociated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences
(n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible
impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a
3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to
the Wild type and seven mutant structures.
Description
Keywords
Cameroon, Molecular modelling, Dolutegravir drug, World Health Organization (WHO), HIV-1
Citation
Mikasi, S. G. et al. (2021). Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations. BMC Infectious Diseases, 21(1),379. https://doi.org/10.1186/s12879-021-06059-x